In a move that elicited rare agreement among groups representing consumers and the pharmaceutical industry, the European Commission proposed various steps to accelerate the approval of drugs and devices by European Union member states.

Although the proposal follows more than 20 years of voluntary cooperation, the commission is hoping to memorialize the effort in order to streamline procedures that so medical products can reach patients faster and companies can more easily seek regulatory approvals.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy